Indicated for the treatment of adult patients with: 🔹 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Both treatment-naive and relapsed/refractory patients. 🔹 Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.

Dosage and administration

Packaging: 100 mg capsules. ⚠️ ADMINISTRATION PROTOCOL: Recommended Dose: 100 mg orally twice daily (approximately every 12 hours). Food Intake: Can be taken with or without food. Important Warning: ⛔ Avoid taking with proton pump inhibitors (PPIs) like omeprazole, as gastric acid is needed for absorption. Administration: Swallow whole with water. Do not chew, crush, or open capsules. Supply: One pack (60 caps) provides a full 30-day supply.

Hypersensitivity to Acalabrutinib. Pregnancy and breastfeeding (risk of fetal harm). Severe bleeding disorders. Active severe infections.

Common adverse reactions include: 🤯 Headache: Very common (often manageable and diminishes over time). 🩸 Hematologic: Bruising, increased risk of bleeding/hemorrhage, neutropenia. 📉 Gastrointestinal: Diarrhea, nausea. 🦠 Infections: Upper respiratory tract infections.

Acaluxen — Acalabrutinib 100 mg, 60 pcs, Everest

100% original product

Active ingredient

Acalabrutinib

Manufacturer

Everest

Dosage 100 mg

Dosage form Capsules

Capsules per pack 60

Acaluxen (Acalabrutinib) 100 mg Capsules

Name: Acaluxen
Brand: Everest
SKU: PROD-151
Price: 29446 UAH
Availability: InStock

29446₴ ~~33841₴~~ -13%

Acaluxen 100 mg (Acalabrutinib) is a highly selective, second-generation Bruton's tyrosine kinase (BTK) inhibitor.

Manufacturer: Everest Pharmaceuticals. Each pack contains 60 capsules. By binding to the BTK enzyme, it inhibits the proliferation and survival of malignant B-cells. It is designed to be more targeted than first-generation inhibitors, potentially reducing off-target toxicities.

Key Feature:

Effective management of CLL and MCL with a generally favorable safety profile, particularly regarding cardiovascular risks compared to Ibrutinib.

Indicated for the treatment of adult patients with:

🔹 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Both treatment-naive and relapsed/refractory patients.
🔹 Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.

Packaging: 100 mg capsules.

⚠️ ADMINISTRATION PROTOCOL:

Recommended Dose: 100 mg orally twice daily (approximately every 12 hours).
Food Intake: Can be taken with or without food.
Important Warning: ⛔ Avoid taking with proton pump inhibitors (PPIs) like omeprazole, as gastric acid is needed for absorption.
Administration: Swallow whole with water. Do not chew, crush, or open capsules.
Supply: One pack (60 caps) provides a full 30-day supply.

Hypersensitivity to Acalabrutinib.
Pregnancy and breastfeeding (risk of fetal harm).
Severe bleeding disorders.
Active severe infections.

Common adverse reactions include:

🤯 Headache: Very common (often manageable and diminishes over time).
🩸 Hematologic: Bruising, increased risk of bleeding/hemorrhage, neutropenia.
📉 Gastrointestinal: Diarrhea, nausea.
🦠 Infections: Upper respiratory tract infections.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.03.2026

Active ingredient

Acalabrutinib

Manufacturer

Everest

Dosage 100 mg

Dosage form Capsules

Capsules per pack 60

100% original product

Delivery across Ukraine

Alternatives

What Customers Say

No reviews yet

Your review can be the first!

Acaluxen (Acalabrutinib) 100 mg Capsules

Similar products

Acabrunat

Acalnib

What Customers Say

No reviews yet

Contact us

Request a call